<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064672</url>
  </required_header>
  <id_info>
    <org_study_id>BALLOONGBS- HMO-CTIL</org_study_id>
    <nct_id>NCT03064672</nct_id>
  </id_info>
  <brief_title>Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial</brief_title>
  <official_title>Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective cohort study aims to determine whether maternal and neonatal outcomes are&#xD;
      affected by GBS carrier status in women undergoing transcervical balloon catheter insertion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse neonatal outcomes</measure>
    <time_frame>2-3 days</time_frame>
    <description>the incidence of composite adverse neonatal outcomes based on the NICE criteria for early detection of neonatal sepsis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite adverse maternal outcomes</measure>
    <time_frame>2-3 days</time_frame>
    <description>chorioamnionitis, suspected chorioamnionitis or endometritis, urinary tract infection or sepsis in the peripartum period, prolonged hospital stay, and allergic reaction to antibiotics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>GBS</condition>
  <arm_group>
    <arm_group_label>induction by transcervical Balloon Catheters insertion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>induction without transcervical Balloon Catheters</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcervical Balloon Catheters</intervention_name>
    <description>induction of labor by transcervical Balloon Catheters insertion</description>
    <arm_group_label>induction by transcervical Balloon Catheters insertion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  During the study period and in the absence of contraindications, women anticipating&#xD;
             induction of labor with unripe cervix will be screened for eligibility.&#xD;
&#xD;
          -  Inclusion criteria are singleton gestation with confirmed cephalic presentation&#xD;
&#xD;
          -  Gestational age between 37+0/7 and 41+6/7 weeks'&#xD;
&#xD;
          -  Intact membranes&#xD;
&#xD;
          -  Reactive non-stress test and Bishop's score &lt; 6.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women less than 18 years, with multiple gestation pregnancies, pregnancies with major&#xD;
             fetal anomalies, vaginal infection, intrauterine fetal death and those who were not&#xD;
             candidates for vaginal delivery (placenta previa, non-cephalic presentation, planned&#xD;
             cesarean delivery).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doron Kabiri, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myriam Safrai, MD</last_name>
    <phone>972-506998982</phone>
    <email>myriamsafrai@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lemberg,, PhD</last_name>
    <phone>972-508946898</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <reference>
    <citation>Kabiri D, Hants Y, Yarkoni TR, Shaulof E, Friedman SE, Paltiel O, Nir-Paz R, Aljamal WE, Ezra Y. Antepartum Membrane Stripping in GBS Carriers, Is It Safe? (The STRIP-G Study). PLoS One. 2015 Dec 31;10(12):e0145905. doi: 10.1371/journal.pone.0145905. eCollection 2015.</citation>
    <PMID>26719985</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data of the mother and the baby will be checked and recorded. At the end of the study, all the data are gonna be analyzed. In case of a severe bad outcome, the data will be checked during the study to make sure that the study is not the cause.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

